These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Structures of RGL1 RAS-Association Domain in Complex with KRAS and the Oncogenic G12V Mutant. Eves BJ; Gebregiworgis T; Gasmi-Seabrook GMC; Kuntz DA; Privé GG; Marshall CB; Ikura M J Mol Biol; 2022 May; 434(9):167527. PubMed ID: 35257782 [TBL] [Abstract][Full Text] [Related]
24. Backbone assignment and secondary structure of Rnd1, an unusual Rho family small GTPase. Cao S; Mao X; Liu D; Buck M Biomol NMR Assign; 2013 Oct; 7(2):121-8. PubMed ID: 22618864 [TBL] [Abstract][Full Text] [Related]
25. Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex. Damianou A; Liang Z; Lassen F; Vendrell I; Vere G; Hester S; Charles PD; Pinto-Fernandez A; Santos A; Fischer R; Kessler BM Life Sci Alliance; 2024 May; 7(5):. PubMed ID: 38453365 [TBL] [Abstract][Full Text] [Related]
26. KRAS is vulnerable to reversible switch-II pocket engagement in cells. Vasta JD; Peacock DM; Zheng Q; Walker JA; Zhang Z; Zimprich CA; Thomas MR; Beck MT; Binkowski BF; Corona CR; Robers MB; Shokat KM Nat Chem Biol; 2022 Jun; 18(6):596-604. PubMed ID: 35314814 [TBL] [Abstract][Full Text] [Related]
27. NMR backbone and methyl resonance assignments of an inhibitory G-alpha subunit in complex with GDP. Goricanec D; Hagn F Biomol NMR Assign; 2019 Apr; 13(1):131-137. PubMed ID: 30539422 [TBL] [Abstract][Full Text] [Related]
28. 1D and 2D NMR for KRAS:Ligand Binding. Cornilescu G Methods Mol Biol; 2024; 2797():115-124. PubMed ID: 38570456 [TBL] [Abstract][Full Text] [Related]
29. KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation. Lu J; Bera AK; Gondi S; Westover KD Biochemistry; 2018 Jan; 57(3):324-333. PubMed ID: 29235861 [TBL] [Abstract][Full Text] [Related]
30. Antipsychotic phenothiazine drugs bind to KRAS in vitro. Wang X; Gorfe AA; Putkey JA J Biomol NMR; 2021 Jul; 75(6-7):233-244. PubMed ID: 34176062 [TBL] [Abstract][Full Text] [Related]
31. Oncogenic mutations Q61L and Q61H confer active form-like structural features to the inactive state (state 1) conformation of H-Ras protein. Matsumoto S; Taniguchi-Tamura H; Araki M; Kawamura T; Miyamoto R; Tsuda C; Shima F; Kumasaka T; Okuno Y; Kataoka T Biochem Biophys Res Commun; 2021 Aug; 565():85-90. PubMed ID: 34102474 [TBL] [Abstract][Full Text] [Related]
32. Three-dimensional structure and properties of wild-type and mutant H-ras-encoded p21. Wittinghofer A; Franken SM; Scheidig AJ; Rensland H; Lautwein A; Pai EF; Goody RS Ciba Found Symp; 1993; 176():6-21; discussion 21-7. PubMed ID: 8299426 [TBL] [Abstract][Full Text] [Related]
33. Solution structure of the state 1 conformer of GTP-bound H-Ras protein and distinct dynamic properties between the state 1 and state 2 conformers. Araki M; Shima F; Yoshikawa Y; Muraoka S; Ijiri Y; Nagahara Y; Shirono T; Kataoka T; Tamura A J Biol Chem; 2011 Nov; 286(45):39644-53. PubMed ID: 21930707 [TBL] [Abstract][Full Text] [Related]
34. Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation. Sad K; Parashar P; Tripathi P; Hungyo H; Sistla R; Soni R; Tandon V Free Radic Biol Med; 2021 Dec; 177():299-312. PubMed ID: 34742922 [TBL] [Abstract][Full Text] [Related]
35. The dynamicity of mutant KRAS β2 strand modulates its downstream activation and predicts anticancer KRAS inhibition. Pashapour Anousheh J; Barzegar A; Hejazi MS; Mehdizadeh Aghdam E Life Sci; 2022 Dec; 310():121053. PubMed ID: 36228769 [TBL] [Abstract][Full Text] [Related]
36. ¹H, ¹³C and ¹⁵N resonance assignment for the human K-Ras at physiological pH. Vo U; Embrey KJ; Breeze AL; Golovanov AP Biomol NMR Assign; 2013 Oct; 7(2):215-9. PubMed ID: 22886485 [TBL] [Abstract][Full Text] [Related]
37. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS. Roskoski R Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320 [TBL] [Abstract][Full Text] [Related]
38. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy. Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X Mol Cancer; 2019 Apr; 18(1):85. PubMed ID: 30971271 [TBL] [Abstract][Full Text] [Related]
39. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722 [TBL] [Abstract][Full Text] [Related]
40. Crystal structures at 2.2 A resolution of the catalytic domains of normal ras protein and an oncogenic mutant complexed with GDP. Tong LA; de Vos AM; Milburn MV; Kim SH J Mol Biol; 1991 Feb; 217(3):503-16. PubMed ID: 1899707 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]